chronic hypertension in pregnancy

in review 3 min read Updated 2026-10-18
chronic hypertension in pregnancy

HTN before conception or <20 wk. Treat at ≥140/90, target DBP 85 (CHIPS achieved SBP ~133); <130/80 if pregestational diabetes . Labetalol, nifedipine XL, methyldopa first-line. ACEi/ARB stop at positive pregnancy test. Baseline uPCR + Cr early — without it, superimposed preeclampsia can’t be called later. Aspirin from 12–16 wk.

treatment thresholds and targets

  • Start/continue therapy at average ≥140/90 — don’t wait for severe range (CHAP (2022))
  • Target DBP 85 (CHIPS (2015)); in practice SBP 130–140
  • Pregestational DM: <130/80
  • BP falls ~10% in first/second trimester → some can reduce or stop therapy; re-escalate from ~20 wk
  • 2025 Canadian primary-care HTN guideline explicitly excludes pregnancy — use SOGC

oral agents

SOGC 2022 titration (start monotherapy; add a second class before maxing if needed, up to 3 drugs):

druglowmediumhighmaxcaution
labetalol100 mg TID–QID200 mg TID–QID300 mg TID–QID1200 mg/dcontraindicated in poorly controlled asthma; neonatal bradycardia/hypoglycaemia → newborn glucose screen
nifedipine XL30 mg daily30 mg BID or 60 mg daily30 mg AM + 60 mg PM120 mg/dcontraindicated in aortic stenosis; ensure XL
methyldopa250 mg TID–QID500 mg TID–QID750 mg TID2500 mg/ddepression, sedation, LFT rise
  • Other first-line β-blockers: metoprolol, propranolol, acebutolol, pindolol
  • Second-line: clonidine, hydralazine, thiazides (continue if pre-existing); amlodipine — insufficient data
  • Starting doses are higher than non-pregnant (faster clearance)
stop before or at conception
  • ACEi/ARB, direct renin inhibitors — fetopathy (renal agenesis/dysgenesis, oligohydramnios, pulmonary hypoplasia, skull hypoplasia), mostly T2–T3 → switch pre-conception or at positive test; proteinuric CKD/diabetic nephropathy may continue until positive test
  • atenolol — FGR (and neonatal bradycardia via breast milk)
  • spironolactone — antiandrogenic; limited data
  • prazosin — limited data, avoid peripartum
  • Postpartum/breastfeeding (SOGC): labetalol, methyldopa, nifedipine, enalapril, captopril — resume ACEi for proteinuria postpartum

baseline workup (first visit)

  • CBC, Cr, electrolytes, AST/ALT, uPCR (or uACR), urinalysis
  • ECG if long-standing/severe; echo if LVH or symptoms
  • Secondary HTN screen if young, resistant, or suggestive features (aldosteronism, renal artery stenosis, phaeochromocytoma, CKD) — workup limited in pregnancy, prioritise pre-conception
  • Aspirin 81–162 mg qhs from 12–16 wk to 36 wk
  • Growth ultrasound surveillance (FGR, SGA)
  • Delivery: expectant to 37 wk if well; offer induction 38⁺⁰–39⁺⁶, advise from 40⁺⁰ wk

superimposed preeclampsia

Diagnose when, on chronic HTN:

  • new/worsening proteinuria vs documented baseline, or
  • any adverse condition (symptoms, plt <100, ↑AST/ALT, ↑Cr, foetal growth restriction), or
  • resistant HTN (needs ≥3 agents) after 20 wk

Management → hypertensive disorders of pregnancy. Higher perinatal mortality than preeclampsia arising from gestational HTN.

new proteinuria on chronic HTN

27 wk, nifedipine XL, BP 154/96, uPCR 72 (baseline 12), Cr 83, plt 145. This is superimposed preeclampsia until proven otherwise → admit/urgent obstetric review, symptoms, labs, foetal assessment. Cr 83 µmol/L is already abnormal in pregnancy (see physiology and lab interpretation in pregnancy).


complications

  • Maternal: superimposed preeclampsia (~20–25%), abruption, stroke, AKI, HF
  • Foetal: FGR/SGA, preterm birth (often iatrogenic), stillbirth

evidence

  • CHAP (2022) — n=2408, mild CHTN <23 wk; treat to <140/90 vs only if ≥160/105: composite (severe preeclampsia, PTB <35 wk, abruption, foetal/neonatal death) 30.2% vs 37.0%; no ↑ SGA
  • CHIPS (2015) — n=987; DBP 85 vs 100: no perinatal difference; less-tight → more severe maternal HTN

Prepared 2026-10-18. Not yet verified — check every number against the sources.

Key references

+1 more source

Suggest a correction chronic hypertension in pregnancy